Loading patent…
AssigneesRibomic Inc., Cellmid Limited
InventorsAkio Suzumura, Jinyan Wang, Takashi Matsui, Sadatoshi Sakuma, Shin Miyakawa, Masatoshi Fujiwara, Yoshikazu Nakamura
Estimating the term…
The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.
1-8. (canceled)
A method for increasing number of regulatory T cells comprising of inhibition of Midkine.
A method for increasing number of regulatory T cells comprising of administration of a Midkine inhibitor.
A use of a Midkine inhibitor in the manufacture of an expansive agent for regulatory T cell population.
A method for the treatment or prevention of disease associated with the functional disorder of regulatory T cells comprising of inhibition of Midkine.
A method for the treatment or prevention of disease associated with the functional disorder of regulatory T cells comprising of administration of a Midkine inhibitor.
A use of a Midkine inhibitor in the manufacture of a therapeutic or preventive agent for disease associated with the functional disorder of regulatory T cells.
A method for screening a medicament for the treatment or prevention of disease associated with the functional disorder of regulatory T cells by binding to the expressed Midkine, comprising:
A method for screening a drug composition for the treatment or prevention of disease associated with the functional disorder of regulatory T cells by inhibiting Midkine expression, comprising:
A method for screening a medicament for the treatment or prevention of disease associated with the functional disorder of regulatory T cells by inhibiting Midkine expression, comprising:
A method for screening a medicament for the treatment or prevention of diseases associated with the functional disorder of regulatory T cells by inhibiting Midkine activity, comprising:
A method of diagnosing diseases associated with the functional disorder of regulatory T cells comprising a step of assaying the Midkine expression level.
A diagnostic agent for diseases associated with the functional disorder of regulatory T cells comprising a substance that binds to Midkine.
Dependencies are inferred from the claim text.